[Alpha Biz= Paul Lee] KOSPI-listed HanAll Biopharma announced on January 21 that its consolidated operating loss for 2025 was approximately KRW 920 million, a reversal from the KRW 230 million operating profit recorded in the previous year.
The company cited increased selling and administrative expenses as a factor that dampened profitability.
Consolidated revenue rose 11.7% year-on-year to KRW 155.2 billion, while net loss widened to KRW 5.6 billion.
In the fourth quarter, the company posted an operating loss of KRW 2 billion, compared with an operating profit of KRW 2.7 billion in the same period last year. Quarterly revenue and net loss were KRW 37.5 billion and KRW 6.2 billion, respectively.
Revenue from the pharmaceutical segment increased 13% year-on-year to KRW 133.8 billion. Probiotic drug BioTop led growth with sales of KRW 23.8 billion, and the company expects BioTop sales to reach approximately KRW 30 billion in 2026.
The company’s hair loss treatment portfolio also exceeded annual sales of KRW 10 billion, leveraging its competitiveness in niche markets.
HanAll Biopharma plans to expand its product portfolio by launching eight new products this year. The company anticipates accelerated growth with the upcoming release of clinical results from five trials across three products.
Key milestones expected in 2026 include Phase 3 results for Batoclimab in Thyroid Eye Disease (TED), top-line data from the registration trial of ImeroPrubat in difficult-to-treat Rheumatoid Arthritis (D2T RA), and early PoC results for Cutaneous Lupus Erythematosus (CLE). VELOS-4 Phase 3 top-line results for dry eye treatment Tanpanacept are also scheduled for release later this year. Additionally, development of Parkinson’s treatment HL192 is progressing toward the next clinical stage within the year.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
